Cover Image
市場調查報告書

歐洲的老年癡呆症治療藥的開發平台分析

Europe Alzheimer Drug Pipeline Analysis

出版商 PNS Pharma 商品編碼 302558
出版日期 內容資訊 英文 265 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
歐洲的老年癡呆症治療藥的開發平台分析 Europe Alzheimer Drug Pipeline Analysis
出版日期: 2014年01月14日 內容資訊: 英文 265 Pages
簡介

近年來歐洲老年癡呆症的患病率正在增加,一般預測今後數年也將同樣上升。預測今後數十年,歐洲老年癡呆症的得病率將會激增,相信這將帶給該地區社會保健制度極大的壓力。在面臨老年癡呆症流行的當下,開發治療或修飾疾病的治療法便是當務之急。

本報告提供歐洲正在開發的各種老年癡呆症治療藥詳細調查,提供各開發階段簡介,適應症,作用機制,品牌名,藥物類別,相關經營者,專利資料等彙整資料,為您概述為以下內容。

第1章 歐洲的老年癡呆症市場概要

第2章 老年癡呆症臨床階段:不明階段

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第3章 老年癡呆症臨床階段:研究階段

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第4章 老年癡呆症臨床階段:臨床試驗前

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第5章 老年癡呆症臨床階段:臨床試驗

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第6章 老年癡呆症臨床階段:PhaseⅠ

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第7章 老年癡呆症臨床階段:PhaseⅠ/Ⅱ

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第8章 老年癡呆症臨床階段:PhaseⅡ

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第9章 老年癡呆症臨床階段:PhaseⅡ/Ⅲ

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第10章 老年癡呆症臨床階段:PhaseⅢ

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第11章 老年癡呆症臨床階段:預備登記

  • 概要
  • 老年癡呆症治療藥臨床階段的簡介

第12章 上市

  • 概要
  • 已上市老年癡呆症治療藥
目錄

The incidence of Alzheimer's disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer's disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure on the social and health-care systems of the region. There is an urgent need for developing curative or disease-modifying therapies to offset the upcoming Alzheimer's disease epidemic.

"Europe Alzheimer's Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in "Europe Alzheimer's Drug Pipeline Analysis" research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

Europe Alzheimer's Disease Drug Pipeline by Clinical Phase:

  • Research: 19
  • Preclinical: 49
  • Clinical: 1
  • Phase-I: 25
  • Phase-I/II: 2
  • Phase-II: 26
  • Phase-II/III: 2
  • Phase-III: 5
  • Preregistration: 2
  • Marketed: 10
  • Unknown: 1

Table of Contents

1. Europe Alzheimer's Disease Market Overview

2. Alzheimer's Disease Drug Clinical Phase: Unknown

  • 2.1. Overview
  • 2.2. Alzheimer's Disease Drug Profile in Clinical Phase

3. Alzheimer's Disease Drug Clinical Phase: Research

  • 3.1. Overview
  • 3.2. Alzheimer's Disease Drug Profile in Clinical Phase

4. Alzheimer's Disease Drug Clinical Phase: Preclinical

  • 4.1. Overview
  • 4.2. Alzheimer's Disease Drug Profile in Clinical Phase

5. Alzheimer's Disease Drug Clinical Phase: Clinical

  • 5.1. Overview
  • 5.2. Alzheimer's Disease Drug Profile in Clinical Phase

6. Alzheimer's Disease Drug Clinical Phase: Phase-I

  • 6.1. Overview
  • 6.2. Alzheimer's Disease Drug Profile in Clinical Phase

7. Alzheimer's Disease Drug Clinical Phase: Phase-I/II

  • 7.1. Overview
  • 7.2. Alzheimer's Disease Drug Profile in Clinical Phase

8. Alzheimer's Disease Drug Clinical Phase: Phase-II

  • 8.1. Overview
  • 8.2. Alzheimer's Disease Drug Profile in Clinical Phase

9. Alzheimer's Disease Drug Clinical Phase: Phase-II/III

  • 9.1. Overview
  • 9.2. Alzheimer's Disease Drug Profile in Clinical Phase

10. Alzheimer's Disease Drug Clinical Phase: Phase-III

  • 10.1. Overview
  • 10.2. Alzheimer's Disease Drug Profile in Clinical Phase

11. Alzheimer's Disease Drug Clinical Phase: Preregistration

  • 11.1. Overview
  • 11.2. Alzheimer's Disease Drug Profile in Clinical Phase

12. Marketed

  • 12.1. Overview
  • 12.2. Marketed Drug Profile

List of Table

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top